UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

Technical considerations for isolated limb perfusion: Results of an expert consensus group Delphi process (Presented on behalf of the Isolated Limb Perfusion Expert Consensus Group)

European journal of surgical oncology, 2024-02, Vol.50 (2), p.107401, Article 107401

2024

Volltextzugriff (PDF)

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

Journal of thoracic oncology, 2020-05, Vol.15 (5), p.803-815

2020

Volltextzugriff (PDF)

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Journal of thoracic oncology, 2015-01, Vol.10 (1), p.156-163

2015

Volltextzugriff (PDF)

What could the future hold for treatment sequencing in cancer medicine? An interview with Angela Märten

Future oncology (London, England), 2019-09, Vol.15 (25), p.2891-2893

2019

Volltextzugriff (PDF)

A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4179-TPS4179

2023

Volltextzugriff (PDF)

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)

Lung cancer (Amsterdam, Netherlands), 2019-01, Vol.127, p.103-111

2019

Volltextzugriff (PDF)

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

Future oncology (London, England), 2018-11, Vol.14 (27), p.2861-2874

2018

Volltextzugriff (PDF)

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study

Future oncology (London, England), 2019-09, Vol.15 (25), p.2905-2914

2019

Volltextzugriff (PDF)

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3004-3004

2022

Volltextzugriff (PDF)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Advances in therapy, 2020-02, Vol.37 (2), p.759-769

2020

Volltextzugriff (PDF)

Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9072-9072

2021

Volltextzugriff (PDF)

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2019-06, Vol.132, p.126-131

2019

Volltextzugriff (PDF)

Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

OncoTargets and therapy, 2024-01, Vol.17, p.267-280

2024

Volltextzugriff (PDF)

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

Journal of cancer research and clinical oncology, 2019-06, Vol.145 (6), p.1569-1579

2019

Volltextzugriff (PDF)

Afatinib in Non‐Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

The oncologist (Dayton, Ohio), 2015-10, Vol.20 (10), p.1167-1174

2015

Volltextzugriff (PDF)

Pankomab : a potent new generation anti-tumour MUC1 antibody

Cancer Immunology, Immunotherapy, 2006-11, Vol.55 (11), p.1337-1347

2006

Volltextzugriff (PDF)

Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive ( EGFR m+) advanced NSCLC

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21060-e21060

2018

Volltextzugriff (PDF)

5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I

Journal of immunotherapy (1997), 2012-04, Vol.35 (3), p.245

2012

Volltextzugriff (PDF)

Experience With Afatinib in Patients With Non‐Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

The oncologist (Dayton, Ohio), 2014-10, Vol.19 (10), p.1100-1109

2014

Volltextzugriff (PDF)

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

OncoTargets and therapy, 2018-01, Vol.11, p.8575-8587

2018

Volltextzugriff (PDF)

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)

The patient : patient-centered outcomes research, 2018-02, Vol.11 (1), p.131-141

2018

Volltextzugriff (PDF)

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

BMC cancer, 2014-08, Vol.14 (1), p.624-624, Article 624

2014

Volltextzugriff (PDF)

First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9046-9046

2016

Volltextzugriff (PDF)

Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked

Cancer Immunology, Immunotherapy, 2010-06, Vol.59 (6), p.829-839

2010

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(59)
Science & Technology
(59)
Humans
(45)
Oncology
(38)
Male
(25)
Female
(21)
Immunotherapy
(19)
Adult
(18)
Biological And Medical Sciences
(18)
Middle Aged
(18)
Aged
(17)
Tumors
(17)
Immunology
(16)
Medicine, Research & Experimental
(16)
Research & Experimental Medicine
(16)
Medical Sciences
(15)
Pancreatic Neoplasms - Drug Therapy
(14)
Pancreatic Neoplasms - Pathology
(13)
Animals
(12)
Afatinib
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Technical considerations for isolated limb perfusion: Results of an expert consensus group Delphi process (Presented on behalf of the Isolated Limb Perfusion Expert Consensus Group)

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

What could the future hold for treatment sequencing in cancer medicine? An interview with Angela Märten

A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib

Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer

Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

Afatinib in Non‐Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Pankomab : a potent new generation anti-tumour MUC1 antibody

Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive ( EGFR m+) advanced NSCLC

5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I

Experience With Afatinib in Patients With Non‐Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs)

Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked

Suchergebnisse filtern